Search Result

Results for "

L1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Payload (1) Akt (9) Aldose Reductase (1) AMPK (6) Amylases (1) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (3) Apolipoprotein (4) Apoptosis (41) Arginase (1) Aryl Hydrocarbon Receptor (1) AUTACs (1) Autophagy (8) Bacterial (10) Bcl-2 Family (9) Beta-lactamase (2) Beta-secretase (2) Biochemical Assay Reagents (7) c-Met/HGFR (1) c-Myc (3) Cadherin (1) CaMK (1) Cannabinoid Receptor (1) Carnitine Palmitoyltransferase (CPT) (1) Caspase (6) CCR (1) CD19 (1) CD3 (3) CD47 (3) CD73 (1) CDK (2) Cholinesterase (ChE) (2) Collagen (1) Connective Peptide (1) COX (4) CTLA-4 (2) CXCR (2) Cyclic GMP-AMP Synthase (1) Cytochrome P450 (4) Deubiquitinase (5) DNA Stain (1) DNA-PK (1) DNA/RNA Synthesis (7) Drug Derivative (2) Drug Intermediate (2) Drug-Linker Conjugates for ADC (3) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (3) EGFR (6) Endogenous Metabolite (6) Endonuclease (1) Environmental Pollutants (1) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) ERK (3) Eukaryotic Initiation Factor (eIF) (2) Exosomes (2) FABP (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (2) FGFR (1) Fluorescent Dye (1) Free Fatty Acid Receptor (1) Fungal (4) FXR (1) Galectin (1) GLUT (1) Glutathione Peroxidase (2) Glycosidase (10) GSK-3 (2) HBV (3) HDAC (13) HIF/HIF Prolyl-Hydroxylase (5) Histone Acetyltransferase (1) Histone Demethylase (5) HPV (3) HSP (7) Hsp-targeting Chimeras (1) Hydroxycarboxylic Acid Receptor (HCAR) (1) IFNAR (8) IGF-1R (1) IKK (3) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (6) Interleukin Related (9) Isotope-Labeled Compounds (1) JAK (1) JNK (1) LAG-3 (1) Leukotriene Receptor (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (5) Lipase (1) Liposome (1) LYTACs (3) MAP4K (3) MDM-2/p53 (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (1) MMP (3) MNK (2) Monoamine Oxidase (3) mRNA (2) mTOR (2) MyD88 (1) NAMPT (2) NF-κB (7) NO Synthase (2) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (2) PAK (1) Parasite (1) PARP (3) PD-1/PD-L1 (320) PDK-1 (1) PERK (3) Phosphatase (3) Phosphodiesterase (PDE) (2) Phospholipase (1) PI3K (6) PKC (2) Potassium Channel (1) PPAR (12) Prostaglandin Receptor (1) PROTAC Linkers (4) PROTACs (9) PSMA (1) PTEN (1) Pyroptosis (2) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (3) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (12) Reference Standards (13) RIBOTAC (1) ROR (1) RSV (1) SARS-CoV (2) Scavenger Receptor Class B type I (SR-BI） (1) Ser/Thr Protease (1) Sirtuin (1) Small Interfering RNA (siRNA) (87) SOD (3) Src (2) STAT (12) Stearoyl-CoA Desaturase (SCD) (1) STING (6) Succinate Dehydrogenase (1) Target Protein Ligand-Linker Conjugates (3) TGF-beta/Smad (3) TGF-β Receptor (1) Tim3 (1) TLK (1) TNF Receptor (8) Toll-like Receptor (TLR) (9) Transmembrane Glycoprotein (3) Tryptophan Hydroxylase (1) VEGFR (8) Virus Protease (1) VISTA (2) Wnt (1) α-synuclein (1) β-catenin (1) β-glucuronidase (1)
By Research Areas:	Cancer (381) Cardiovascular Disease (5) Infection (33) Inflammation/Immunology (127) Metabolic Disease (49) Neurological Disease (20)
Click Chemistry:	Labeling and Fluorescence Imaging (1) DBCO (1) Azide (2) Alkynes (1)
Oligonucleotides:	Chemokine & Receptors (2) Aptamers (1) Rat Pre-designed siRNA Sets (14) mRNA (2) Mouse Pre-designed siRNA Sets (14) Human Pre-designed siRNA Sets (59) Antisense Oligonucleotides (7) siRNAs (87)

569

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

126

Recombinant Proteins

Isotope-Labeled Compounds

162

Antibodies

Click Chemistry

Oligonucleotides

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma ^[1].

Durvalumab (anti-PD-L1) 5+ Cited Publications MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

PROTAC PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC PD-L1 degrader-1 is a CRBN-based *PD-L1-PROTAC* degrader with a notable PD-L1 protein degradation capability. PROTAC PD-L1 degrader-1 shows potent PD-L1 degradation in 4T1 cells with a DC₅₀ of 0.609 μM. PROTAC PD-L1 degrader-1 can be used for the study of breast cancer. (Blue: CRBN ligand (HY-150839), Black: linker; Pink: PD-L inhibitor (HY-19745)) ^[1].

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV Apoptosis PDK-1	Infection Neurological Disease Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the *PDK1/Akt* pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats ^[1] .

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner ^[1].

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

PD-1/PD-L1-IN-9 2 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

PD-L1-IN-1 1 Publications Verification	PD-1/PD-L1 Apoptosis	Cancer
PD-L1-IN-1 (Compound 10) is a potent *PD-L1* inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly exhibits low cytotoxicity in healthy cells ^[1].

PD-L1 inhibitory peptide TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers ^[1] .

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23* is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice ^[1].

PD-L1-IN-2 1 Publications Verification	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting *PD-L1. PD-L1-IN-2* is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research ^[1].

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research ^[1].

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) ^[1].

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a *PD-1/PD-L1* inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects ^[1].

L-Threitol L-1,2,3,4-Butanetetrol	Drug Intermediate	Others
L-Threitol (L-1,2,3,4-Butanetetrol) is a four-carbon sugar alcohol. L-Threitol serves as an important pharmaceutical intermediate and can be used in the synthesis of other active compounds, such as anticancer agents and chiral compounds ^[1].

PD-L1 inhibitory peptide	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers ^[1] .

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

PD-L1/HDAC6-IN-1	PD-1/PD-L1 HDAC	Inflammation/Immunology Cancer
PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of *PD-L1* and HDAC6, with IC₅₀ values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma ^[1].

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer ^[1].

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy ^[1].

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

PD-1/PD-L1-IN-9 hydrochloride 2 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

PD-1/PD-L1-IN-28	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of *PD-1/PD-L1* signaling pathway (IC₅₀=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity ^[1].

Gomisin L1	Others	Cancer
Gomisin L1 is a lignan, shows inhibitory effect on cell viability of A2780 and Ishikawa cells, with IC₅₀s of 39.06 μM and 74.16 μM, respectively ^[1].

Anti-HPV18 L1 Antibody (H18L1-A)	HPV	Infection
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases ^[1].

PD-L1-IN-8	PD-1/PD-L1	Cancer
PD-L1-IN-8 is a *PD-L1* inhibitor (IC₅₀ = 0.89 nM). PD-L1-IN-8 shows low CYP inhibition and minimal hERG activity. PD-L1-IN-8 can be used for the study of colon cancer ^[1].

PROTAC PD-L1 degrader-2	PROTACs PD-1/PD-L1	Cancer
PROTAC PD-L1 degrader-2 (Compound 9i) is a PROTAC degrader for *PD-L1, that inhibits PD-L1 with an IC₅₀* of 197.4 nM and exhibits an affinity with PD-L1 with a K_d of 301 nM. PROTAC PD-L1 degrader-2 promotes the internalization of PD-L1 on the cell membrane, and induces PD-L1 degradation via the synergistic effect of the proteasome and lysosomal pathways. PROTAC PD-L1 degrader-2 can activate the immune system, and exhibits antitumor efficacy in MC38 C57BL/6 mouse model ^[1].

PD-L1/Nampt-IN-1	PD-1/PD-L1 NAMPT	Cancer
PD-L1/Nampt-IN-1 is an orally active inhibitor that simultaneously target *PD-L1* and NAMPT (nicotinamide phosphoribosyltransferase) with IC₅₀s value of 63 nM and 582 nM. PD-L1/Nampt-IN-1 demonstrates cross-species affinity with comparable K_D values for hPD-L1 (52.6 nM) and mPD-L1 (49.1 nM), respectively. PD-L1/Nampt-IN-1 effectively inhibits tumor growth by activating the tumor immune microenvironment. PD-L1/Nampt-IN-1 can be used for the study of melanoma ^[1].

Human PD-L1 inhibitor II	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

PD-L1/VISTA-IN-2	PD-1/PD-L1 VISTA	Cancer
PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC₅₀ of 1.4 μM for *PD-L1* and a K_D of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects ^[1].

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research ^[1].

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

PD-1/PD-L1-IN-59	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-59 (Compound MZ51) is a *PD-1/PD-L1* inhibitor with an IC₅₀ of 183 nM. PD-1/PD-L1-IN-59 can be used for the study of triple-negative breast cancer (TNBC) ^[1].

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM ^[1].

PD-L1-IN-7	PD-1/PD-L1	Cancer
PD-L1-IN-7 (compound CB31) is an inhibitor of *PD-L1, which can induce PD-L1 internalization and PD-L1 retention in cells. PD-L1-IN-7* can inhibit the interaction of PD-1/PD-L1 (IC₅₀: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells ^[1].

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

Human PD-L1 inhibitor III	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

783 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L079

Anti-Blood Cancer Compound Library

4,121 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 4,121 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L007

Immunology/Inflammation Compound Library

7,846 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 7,846 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L109

Protein-protein Interaction Inhibitor Library

782 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 782 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Type

HY-171821

PF-08046054 SGN-PDL1V	Fluorescent Dyes
PF-08046054 (SGN-PDL1V) is a *PD-L1*-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors ^[1]

HY-145746

Sulfo-Cy5 azide

Fluorescent Dyes

Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) ^[1] .

HY-D1726

8RK59	Fluorescent Dyes
8RK59, a Bodipy probe, is a potent *UCHL1* (ubiquitin C-terminal hydrolase L1) inhibitor, with an IC₅₀ close to 1 μM. 8RK59 could penetrate and label living cells. BodipyFL-alkyne is coupled to the azide of 8RK64 (HY-148254) using copper(I)-mediated click chemistry, resulting in compound 8RK59 ^[1].

Cat. No.	Product Name	Type

HY-107863

Fructooligosaccharides

Oligolevulose

Biochemical Assay Reagents

Fructooligosaccharides (Oligolevulose) are a class of orally active dietary fibers and prebiotics. Fructooligosaccharides exist in foods such as breast milk, wheat, honey, onions, garlic and bananas. Fructooligosaccharides resist hydrolysis by the body's digestive enzymes and stimulate the growth of beneficial intestinal bacteria through colonic fermentation. Fructooligosaccharides significantly prevent bone loss in the femur and lumbar spine ^[1] .

HY-W012846A

L-Threitol L-1,2,3,4-Butanetetrol	Biochemical Assay Reagents
L-Threitol (L-1,2,3,4-Butanetetrol) is a four-carbon sugar alcohol. L-Threitol serves as an important pharmaceutical intermediate and can be used in the synthesis of other active compounds, such as anticancer agents and chiral compounds ^[1].

HY-I0422

L-Porretine L-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid	Biochemical Assay Reagents
L-Porretine is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Research Area

HY-P10375

BMS-986189	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC₅₀ of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 ^[1] .

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238 is an orally active macrocyclic peptide *PD-L1* inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas ^[1] .

HY-P10439

CVRARTR	PD-1/PD-L1	Inflammation/Immunology Cancer
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research ^[1] .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression ^[1].

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P10950A

PD-L1 inhibitory peptide TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers ^[1] .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P10733

LAH4-L1	Peptides	Others
LAH4-L1 Is a histidine-rich cell penetrating peptide. LAH4-L1 can form complexes with DNA or siRNA and help their transport ^[1].

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1* expression.* [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes ^[1].

HY-P10862

AH-D peptide	Exosomes Virus Protease	Infection Cancer
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with IC₅₀ values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1 ⁺ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis ^[1] .

HY-P10950

PD-L1 inhibitory peptide	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers ^[1] .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P5407

HD5	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer ^[1] .

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind *PD-L1* protein, significantly block the interaction between *PD-1* and *PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP*-1 can be used in cancer immunotherapy research ^[1].

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-P10978

NK224	PD-1/PD-L1	Cancer
NK224 is a peptide-based radiotracer targeting human *PD-L1, with dual-radionuclide ( ⁶⁸Ga and ¹⁸F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC₅₀* value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) ^[1].

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) ^[1].

HY-P11110

RK-10	PD-1/PD-L1	Cancer
RK-10 is a *PD-L1* binding peptide. RK-10 conjugated with Cy5 (HY-D0821) or Biotin (HY-B0511) can used to detect PD-L1 expressing tumors with flow cytometry or immunohistochemistry. RK-10 can be used for cancers like NSCLC, breast cancer, squamous cell carcinoma and melanoma detection research ^[1].

HY-125357

Ternatin	Peptides	Metabolic Disease
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC₅₀ of 0.027 μM in *3T3-L1* adipocytes ^[1].

HY-P11347

NOTA-AUNP-12	PD-1/PD-L1	Cancer
NOTA-AUNP-12 is a *PD-L1* antagonist (IC₅₀=2.24×10 ⁻⁷ M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers) ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P2470

Human PD-L1 inhibitor II	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor II is a potent *PD-L1* inhibitor with anti-cancer activity ^[1].

HY-P2474

Human PD-L1 inhibitor I	PD-1/PD-L1	Cancer
Human PD-L1 inhibitor I is a *hPD-1* peptide ligand, with a K_D of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P2564

Human PD-L1 inhibitor III	PD-1/PD-L1	Inflammation/Immunology Cancer
Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

HY-P5276

Human membrane-bound PD-L1 polypeptide	PD-1/PD-L1	Cancer
Human membrane-bound PD-L1 polypeptide can be used as an antigen to induce *PD-L1* antibody production ^[1].

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model ^[1].

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors ^[1] .

HY-P11483

FJ15596	PD-1/PD-L1	Inflammation/Immunology Cancer
FJ15596 is a *PD-1/PD-L1* blockor. FJ15596 blocks PD-1/PD-L1 binding with an IC₅₀ of 570 nM. FJ15596 restores CD3 ⁺ T cell viability. FJ15596 can be used in cancer immunology research ^[1].

HY-P3440A

NOTA-WL12	Drug Derivative PD-1/PD-L1	Cancer
NOTA-WL12 is a conjugate of WL12 (HY-P3440) (peptide targeting PD-L1) and NOTA (HY-134418) (chelate). NOTA-WL12 shows high binding affinity to the PD-L1 (K_D = 3.012 nM). NOTA-WL12 can be labeled with radioactive isotopes for tumor imaging ^[1].

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors ^[1] .

HY-P5407A

HD5 TFA	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection Cancer
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer ^[1] .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9904

Atezolizumab Maximum Cited Publications 36 Publications Verification MPDL3280A; RG-7446; RO-5541267	PD-1/PD-L1 Apoptosis Autophagy	Cancer
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

HY-P9919

Durvalumab 5+ Cited Publications MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody ^[1]. Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P99675

Ivonescimab 1 Publications Verification AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) ^[1] .

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer ^[1].

HY-108730

Avelumab 5+ Cited Publications Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma ^[1].

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1*. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 ^[1] .

HY-108730A

Avelumab (anti-PD-L1) 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma ^[1].

HY-P9919A

Durvalumab (anti-PD-L1) 5+ Cited Publications MEDI 4736 (anti-PD-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

HY-P99100

Visugromab 2 Publications Verification CTL-002	TGF-beta/Smad PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) ^[1].

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- *PD-L1* antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors ^[1] .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting *PD-L1* and VEGF-A, with immune activation and anti-angiogenic activities. By binding to *PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A* in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy ^[1].

HY-P99052

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma ^[1] .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1] .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1*. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy ^[1] .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1* expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer ^[1] .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12*) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer ^[1] .

HY-P990173

Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived *PD-L1* IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer ^[1] .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal *PD-L1* (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) ^[1] .

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting *PD-L1* and *4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1* inhibitory axis. Acasunlimab can be used in research of cancer ^[1] .

HY-P99944

SHR-1701 Retlirafusp alfa	PD-1/PD-L1 TGF-β Receptor	Cancer
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting *PD-L1* and TGF-β for cancer research ^[1].

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀* of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors ^[1].

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine *PD-L1/B7-H1* IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments ^[1] .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting *PD-L1/CTLA-4*. Erfonrilimab blocks the *PD-L1* and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-P991506

Fetrastobart SGN-PDL1V Antibody; PF-08046054 Antibody	ADC Antibody	Cancer
SGN-PDL1V Antibody is a *PD-L1* targeting antibody. SGN-PDL1V Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821) ^[1].

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research ^[1].

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively ^[1].

HY-P99203

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research ^[1] .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo ^[1].

HY-P99145A

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy ^[1].

HY-P991023

Safimestomig 6MW3211	CD47 PD-1/PD-L1	Cancer
Safimestomig (6MW3211) is an *CD47/PD-L1*-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer ^[1].

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against *CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3* and *4-1BB* signals on T cells, as well as targeting the high expression of CD19 or *PD-L1* on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia ^[1] .

HY-P99785

Opucolimab HLX20; HLX43 antibody	PD-1/PD-L1 ADC Antibody	Cancer
Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research ^[1].

HY-P9996

Reozalimab LY3434172; IBI-318	PD-1/PD-L1	Cancer
Reozalimab is a bispecific antibody targeting to *PD-1/PD-L1*. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research ^[1] .

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research ^[1] .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1*. Anti-Mouse PD-1 Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer ^[1] .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with *PD-L1/PD-L2*, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma ^[1] .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific *PD-1/LAG-3* dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity ^[1] .

HY-P991740

IBI-363	PD-1/PD-L1 Interleukin Related	Cancer
IBI-363 is a *PD-1/IL-2* bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer ^[1].

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990738

Enristomig ES-101; INBRX-105	TNF Receptor PD-1/PD-L1	Inflammation/Immunology Cancer
Enristomig (ES-101) is a multispecific antibody. Enristomig is both a *PD-L1* antagonist and a conditional agonist of *4-1BB*. Enristomig can be used for research on PD-L1 expressing tumors ^[1].

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1 antibody* (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Palverafusp alfa (IMM-2510; SYN-2510) is a *PD-L1/VEGF*-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer ^[1].

HY-P991001

Imzokitug BMS-986340; CCR8.50	Inhibitory Antibodies	Inflammation/Immunology
HY-P991001 is an *CKR-L1*-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) ^[1].

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo ^[1].

HY-P991449

LY3415244	PD-1/PD-L1 Tim3	Cancer
LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research ^[1].

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma ^[1] .

HY-P99903

Simridarlimab IBI-322	PD-1/PD-L1 CD47	Inflammation/Immunology Cancer
Simridarlimab (IBI-322) is a bispecific antibody targeting *PD-L1* and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro ^[1].

Species:	Virus (3) Human (75) Rhesus Macaque (2) Rat (5) Mouse (29) Cynomolgus (7) Rabbit (1) Canine (4)
Tag:	SUMO (2) His (85) Strep (1) Tag Free (11) Avi (8) Myc (3) GST (9) MBP (1) Flag (4) Fc (26)
Source:	HEK293 (76) CHO (2) P. pastoris (2) Sf9 insect cells (15) E. coli (31)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705679

	Cathepsin L1 Protein, Human (HEK293) rHuCathepsin L1, His; Cathepsin L1; Major Excreted Protein; MEP; CTSL1; CTSL	Human	HEK293
	Cathepsin L1 protein is a thiol protease that plays a key role in lysosomal protein degradation, affecting cellular functions such as turnover, antigen processing, and bone remodeling. It dissolves cross-linked TG/thyroglobulin, releasing the thyroid hormone thyroxine (T4) in the thyroid follicular cavity. Cathepsin L1 Protein, Human (HEK293) is the recombinant human-derived Cathepsin L1 protein, expressed by HEK293 .

HY-P7754A

	Cathepsin L1 Protein, Human (HEK293, His) rHuCathepsin L1, His; Cathepsin L1; Major Excreted Protein; MEP; CTSL1; CTSL	Human	HEK293
	Cathepsin L1 protein is a thiol protease that plays a key role in lysosomal protein degradation, affecting cellular functions such as turnover, antigen processing, and bone remodeling. It dissolves cross-linked TG/thyroglobulin, releasing the thyroid hormone thyroxine (T4) in the thyroid follicular cavity. Cathepsin L1 Protein, Human (HEK293, His) is the recombinant human-derived Cathepsin L1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P7754

	Cathepsin L1 Protein, Human (HEK293, His, solution) rHuCathepsin L1, His; Cathepsin L1; Major Excreted Protein; MEP; CTSL1; CTSL	Human	HEK293
	Cathepsin L1 Protein, Human (HEK293, His, solution) is a major cysteine protease that plays a major role in intracellular protein catabolism.

HY-P7753

	Cathepsin L1 Protein, Mouse (HEK293, His) rMuCathepsin L, His; Cathepsin L1; Major excreted protein; p39 cysteine proteinase; CTSL1	Mouse	HEK293
	Cathepsin L Protein, Mouse (HEK293, His) is a lysosomal acid cysteine protease, which is associated with tumor occurrence, development, and metastasis.

HY-P705981

	L1CAM Protein, Cynomolgus (HEK293, His) Neural cell adhesion molecule L1; L1CAM	Cynomolgus	HEK293

HY-P71096

	UCHL1 Protein, Human (His, solution) Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1; UCH-L1; Neuron Cytoplasmic Protein 9.5; PGP 9.5; PGP9.5; Ubiquitin Thioesterase L1; UCHL1	Human	E. coli
	The UCHL1 protein is a multifunctional deubiquitinase that regulates a variety of cellular processes. It maintains synaptic and cardiac function, modulates inflammatory responses, and influences osteoclastogenesis. UCHL1 Protein, Human (His, solution) is the recombinant human-derived UCHL1 protein, expressed by E. coli, with C-His labeled tag.

HY-P73466

	UCHL1 Protein, Mouse (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; UchL1; PGP9.5	Mouse	E. coli
	UCHL1 Protein, a ubiquitin carboxyl-terminal hydrolase, plays a crucial role in protein degradation and regulation of cellular processes.It is involved in maintaining neuronal integrity and has been linked to neurodegenerative diseases.UCHL1 Protein's potential as a biomarker and therapeutic target in neurodegenerative disorders makes it a subject of intense research in the field of neuroscience.UCHL1 Protein, Mouse (His) is the recombinant mouse-derived UCHL1 protein, expressed by E.coli , with N-His labeled tag.

HY-P74483

	UCHL1 Protein, Rat (His) Ubiquitin carboxyl-terminal hydrolase isozyme L1; UCH-L1; UchL1; PGP9.5	Rat	E. coli
	The UCHL1 protein is a ubiquitin proteolytic enzyme essential for processing ubiquitin precursors and hydrolyzing ubiquitinated proteins. As a thiol protease, it specifically cleaves the C-terminal glycine of ubiquitin. UCHL1 Protein, Rat (His) is the recombinant rat-derived UCHL1 protein, expressed by E. coli , with N-10*His labeled tag.

HY-P74791

	L1CAM Protein, Human (HEK293, His, solution) 1 Publications Verification Neural cell adhesion molecule L1; NCAM-L1; CD171; L1CAM; CAML1; MIC5	Human	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a critical role in cell adhesion dynamics and initiation of tyrosine kinase receptor transmembrane signaling. Its importance spans brain development, affecting processes such as neuronal migration, axonal growth, fasciculations, and synaptogenesis. L1CAM Protein, Human (HEK293, His, solution) is the recombinant human-derived L1CAM protein, expressed by HEK293 , with C-His labeled tag.

HY-P75504

	Apolipoprotein L/APOL1 Protein, Human (sf9, His) Apolipoprotein L1; Apo-L; ApoL-I; APOL1; APOL	Human	Sf9 insect cells
	Apolipoprotein L (APOL1) Protein is a member of the apolipoprotein L family. Apolipoprotein L/APOL1 Protein, Human (sf9, His) is the recombinant human-derived Apolipoprotein L/APOL1 protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75503A

	Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His) Apolipoprotein L1; Apo-L; ApoL-I; APOL1; APOL	Mouse	HEK293
	The apolipoprotein AI (APOA1) protein is key to reverse cholesterol transport, promoting tissue efflux, and serves as an important cofactor for lecithin cholesterol acyltransferase (LCAT), promoting cholesterol excretion. As a homodimer, APOA1 is a component of the sperm activating protein complex (SPAP), interacts with APOA1BP, CLU, NDRG1, SCGB3A2, NAXE and YJEFN3, exhibiting multiple molecular associations. Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Apolipoprotein A-I/APOA1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P75503

	Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His, solution) Apolipoprotein L1; Apo-L; ApoL-I; APOL1; APOL	Mouse	HEK293
	The apolipoprotein AI (APOA1) protein is key to reverse cholesterol transport, promoting tissue efflux, and serves as an important cofactor for lecithin cholesterol acyltransferase (LCAT), promoting cholesterol excretion. As a homodimer, APOA1 is a component of the sperm activating protein complex (SPAP), interacts with APOA1BP, CLU, NDRG1, SCGB3A2, NAXE and YJEFN3, exhibiting multiple molecular associations. Apolipoprotein A-I/APOA1 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived Apolipoprotein A-I/APOA1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P700417

	L1CAM Protein, Human (HEK293, C-His) L1 cell adhesion molecule; antigen identified by monoclonal R1 , HSAS, HSAS1, MASA, MIC5, S10, SPG1; neural cell adhesion molecule L1; CD171; antigen identified by monoclonal R1; S10; HSAS; MASA; MIC5; SPG1; CAML1; HSAS1; N-CAML1; NCAM-L1; N-CAM-L1;	Human	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a critical role in cell adhesion dynamics and initiation of tyrosine kinase receptor transmembrane signaling. Its importance spans brain development, affecting processes such as neuronal migration, axonal growth, fasciculations, and synaptogenesis. L1CAM Protein, Human (HEK293, C-His) is the recombinant human-derived L1CAM protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P70532

	S100A9 Protein, Human 1 Publications Verification Protein S100-A9; Calgranulin-B; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain; MRP-14; CAGB; CFAG	Human	E. coli
	S100A9 Protein is an acidic protein. S100A9 Protein activates pro-inflammatory signaling pathways by binding to TLR4/MD2 and RAGE receptors, regulating transcription factors such as NF-κB, CREB-1, STAT3/STAT5, etc. S100A9 Protein forms a heterodimer (calprotectin) with S100A8. S100A9 Protein enhances cytokine secretion under inflammatory stimulation, promotes immune cell migration, regulates vascular endothelial permeability, induces tumor cell apoptosis, and exerts antibacterial effects through metal ion chelation.

HY-P70532A

	S100A9 Protein, Human (His) Protein S100-A9; Calgranulin-B; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain; MRP-14; CAGB; CFAG	Human	E. coli
	The S100A9 protein is a calcium and zinc binder that plays a critical regulatory role in inflammation and immune responses. Its diverse functions include induction of neutrophil chemotaxis, adhesion, enhanced bactericidal activity through SYK, PI3K/AKT and ERK1/2 activation, and promotion of phagocytosis. S100A9 Protein, Human (His) is the recombinant human-derived S100A9 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70531A

	S100A8 Protein, Human (N-His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	E. coli
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (N-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P76586

	S100A8 Protein, Human (sf9, His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	Sf9 insect cells
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (sf9, His) is the recombinant human-derived S100A8 protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P71275

	S100A8 Protein, Rat (His) 4 Publications Verification Protein S100-A8; S100a8; Calgranulin-A; Chemotactic cytokine CP-10; Leukocyte L1 complex light chain; Migration inhibitory factor-related protein 8; MRP-8; Pro-inflammatory S100 cytokine; S100 calcium-binding protein A8; Caga; Mrp8	Rat	E. coli
	S100A8 protein functions as a danger signal in inflammation, activating innate immune cells by binding to receptors like Toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (AGER). This triggers signaling pathways that enhance the pro-inflammatory response. S100A8 Protein, Rat (His) is the recombinant rat-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag.

HY-P700543

	CCR8 Protein, Human (P. pastoris, His, Myc) CCR8; chemokine (C-C motif) receptor 8; CMKBR8, CMKBRL2; C-C chemokine receptor type 8; CDw198; CKR L1; CY6; GPR CY6; TER1; CC chemokine receptor 8; chemokine receptor-like 1; chemokine (C-C) receptor 8; CC chemokine receptor CHEMR1; CC-chemokine receptor chemr1; chemokine (C-C) receptor-like 2; CCR-8; CKRL1; CMKBR8; GPRCY6; CMKBRL2; CC-CKR-8; MGC129966; MGC129973	Human	P. pastoris
	CCR8 Protein-VLP, a receptor for CCL1/SCYA1/I-309, may regulate monocyte chemotaxis and thymic cell line apoptosis. It also acts as an alternative coreceptor with CD4 for HIV-1 infection, facilitating viral entry. The interaction with CCL1 highlights its role in mediating cellular responses to this chemokine, implying a regulatory function in immune and inflammatory processes. CCR8 Protein, Human (P. pastoris, His) is the recombinant human-derived CCR8 protein, expressed by P. pastoris , with C-Myc, C-6*His labeled tag.

HY-P703792

	Protein L1/L1R , Monkeypox virus (His) Virion membrane Protein	Virus	E. coli

HY-P77732

	L1CAM Protein, Mouse (HEK293, His) N-CAM-L1; NCAM-L1; CD171; L1CAM; CAML1; MIC5; CALL; CHL1; CHL-1; FLJ44930; L1CAM-2; MGC132578; HSAS; HSAS1; MASA; S10; SPG1	Mouse	HEK293
	The L1CAM protein is a neural cell adhesion molecule that plays a key role in cell adhesion dynamics and transmembrane signaling during brain development.It contributes to neuronal migration, axonal growth, fasciculation, and synaptogenesis.L1CAM Protein, Mouse (HEK293, His) is the recombinant mouse-derived L1CAM protein, expressed by HEK293 , with C-His labeled tag.

HY-P78633

	PD-L1 Protein, Canine (HEK293, His) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Canine	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Canine (HEK293, His) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78604

	PD-L1 Protein, Rabbit (HEK293, His) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Rabbit	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag. The total length of PD-L1 Protein, Rabbit (HEK293, His) is 220 a.a., with molecular weight of 32-44 kDa.

HY-P78822

	PD-L1 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of PD-L1 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) is 220 a.a., with molecular weight of 65-85 kDa.

HY-P703080

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His-Avi) PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P72301

	Protein L1/L1R, Vaccinia virus (sf9, His, myc) 1 Publications Verification Virion membrane protein M25	Virus	Sf9 insect cells
	Protein L1/L1R is part of the entry fusion complex (EFC) composed of 11 proteins. This complex facilitates the entry of the virion core into the host cytoplasm through a two-step process: lipid mixing of viral and cellular membranes, followed by pore formation. The assembly or stability of the EFC relies on all proteins except OPG095 and OPG053. Protein L1/L1R, Vaccinia virus (sf9, His, myc) is the recombinant Virus-derived protein L1/L1R, expressed by sf9 insect cells , with N-His, C-Myc labeled tag.

HY-P7231

	LD78-beta/CCL3L1 Protein, Human rHuLD78β/CCL3L1; C-C motif chemokine 3-like 1; SCYA3L1	Human	E. coli
	LD78-beta/CCL3L1 Protein, Human is a potent ligand for the HIV-1 co-receptor CCR5, which is essential for viral entry into human host cells.

HY-P77819

	PD-L1 Protein, Mouse (Biotinylated, HEK293, His) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78192

	PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) CD274; PDL1; PD-L1; PD-L1B7 homolog 1; B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P76845

	CL-L1/COLEC10 Protein, Mouse (HEK293, Fc) Collectin-10; Collectin liver protein 1; CL-L1	Mouse	HEK293
	CL-L1/COLEC10, operating as a lectin, displays distinct sugar-binding preferences, with a hierarchy of galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine. Apart from its sugar-binding role, CL-L1/COLEC10 functions as a chemoattractant, suggesting potential engagement in the modulation of cell migration. CL-L1/COLEC10 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CL-L1/COLEC10 protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P72729

	CD39L1/ENTPD2 Protein, Mouse (HEK293, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Mouse	HEK293
	In the nervous system, CD39L1/ENTPD2 protein crucially regulates purinergic neurotransmission by proficiently hydrolyzing ATP and other nucleotides. Remarkably, it exhibits marginal hydrolysis of ADP, emphasizing its specificity and significant role in precisely modulating purinergic signaling pathways. CD39L1/ENTPD2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD39L1/ENTPD2 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72730

	CD39L1/ENTPD2 Protein, Human (HEK293, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Human	HEK293
	CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (HEK293, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76903

	CD39L1/ENTPD2 Protein, Human (sf9, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Human	Sf9 insect cells
	CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (sf9, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P704471

	CD39L1/ENTPD2 Protein, Human (Active, CHO, His) Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2; Cd39L1	Human	CHO
	CD39L1/ENTPD2 protein, expressed in the nervous system, efficiently hydrolyzes ATP and various nucleotides, while showing limited hydrolysis of ADP. Its substrate specificity hierarchy highlights its regulatory role in purinergic signaling and selective nucleotide hydrolysis, contributing to precise control of neurotransmission. CD39L1/ENTPD2 Protein, Human (Active, CHO, His) is the recombinant human-derived CD39L1/ENTPD2 protein, expressed by CHO, with C-His labeled tag.

HY-P703597

	CDC7 Protein, Human (His) CDC7L1	Human	E. coli
	CDC7 Protein, Human (His) is the recombinant human-derived CDC7, expressed by E. coli , with His labeled tag.

HY-P703254

	RAB29 Protein, Human (GST) RAB7L1	Human	E. coli
	RAB29 Protein, Human (GST) is the recombinant human-derived RAB29, expressed by E. coli , with GST labeled tag. ,

HY-P7397

	PD-L1 Protein, Human (CHO, Fc) 1 Publications Verification rHuPD-L1, Fc Chimera; Programmed death ligand 1; CD274; B7-H1	Human	CHO
	PD-L1 Protein, Human (CHO, Fc) play a major role in suppressing the adaptive arm of immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

HY-P7398

	PD-L1 Protein, Human (HEK293, His) rHuPD-L1, His; Programmed death ligand 1; CD274; B7-H1	Human	HEK293
	PD-L1 Protein is an important immunoregulatory molecule and a member of the B7 superfamily. As the primary ligand of PD-1, PD-L1 Protein can bind to PD-1 to inhibit T-cell activation, proliferation, and cytokine secretion, and induce T-cell apoptosis. PD-L1 Protein plays a key role in tumor immune escape and immune homeostasis regulation. PD-L1 Protein, Human (HEK293, His) is a recombinant PD-L1 protein expressed by HEK293 with a C-His His tag.

HY-P77340

	CL-L1/COLEC10 Protein, Cynomolgus (HEK293, Fc) Collectin-10; Collectin liver protein 1; CL-L1; Collectin-34; CL-34	Cynomolgus	HEK293
	CL-L1/COLEC10, operating as a lectin, displays distinct sugar-binding preferences, with a hierarchy of galactose > mannose = fucose > N-acetylglucosamine > N-acetylgalactosamine. Apart from its sugar-binding role, CL-L1/COLEC10 functions as a chemoattractant, suggesting potential engagement in the modulation of cell migration. CL-L1/COLEC10 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CL-L1/COLEC10 protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P70564

	PD-L1 Protein, Cynomolgus (HEK293, His) B7-H; B7H1; B7-H1; PDCD1L1; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73361

	PD-L1 Protein, Human (HEK293) Maximum Cited Publications 9 Publications Verification Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Human	HEK293
	The PD-L1 protein critically regulates immune tolerance by acting as a ligand for PDCD1/PD-1, regulating T cell activation threshold, and limiting effector responses. It may act as a costimulatory molecule for IL10-producing T cell subsets. PD-L1 Protein, Human (HEK293) is the recombinant human-derived PD-L1 protein, expressed by HEK293 , with tag free.

HY-P71008

	PD-L1 Protein, Cynomolgus (HEK293, Fc) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293
	CD274 molecule, also known as programmed death ligand 1 (PD-L1), binds to the checkpoint suppressor molecule PD-1 to inhibit TCR-mediated IL-2 production and T cell proliferation signaling. PD-L1 is involved in the PI3K/JAK/STAT signaling pathway to promote tumor occurrence. PD-L1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73364

	PD-L1 Protein, Rat (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73365

	PD-L1 Protein, Rat (HEK293, His) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Rat	HEK293
	PD-L1 (Programmed death-ligand 1) critically regulates T cell proliferation and migration, acting as a biomarker for periodontitis and pre-eclampsia. CD274 is its human ortholog. Biased expression in the thymus (RPKM 102.9), spleen (RPKM 58.3), and other tissues emphasizes PD-L1's centrality in immune regulation across diverse physiological and pathological conditions. PD-L1 Protein, Rat (HEK293, His) is the recombinant rat-derived PD-L1 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P73717

	PD-L1 Protein, Canine (HEK293, Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Canine	HEK293
	PD-L1 Protein, Canine (HEK293, Fc) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response. The amino acid sequence of PD-L1 is encoded by 7 exons, which form a protein of ~40 kDa. PD-L1 is a type I transmembrane protein, is part of the immunoglobulin (Ig) superfamily and is composed of IgV-like and IgC-like extracellular domains, a hydrophobic transmembrane domain and a short cytoplasmic tail composed of 30 amino acids. PD-L1 can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. PD-L1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived PD-L1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P703566

	ETF1 Protein, Human ERF1; RF1; SUP45L1	Human	E. coli
	ETF1 Protein, Human is the recombinant human-derived ETF1, expressed by E. coli , with tag Free labeled tag.

HY-P7769

	LD78-beta/CCL3L1 Protein, Human (HEK293 His) rHuCCL3L1, His; C-C Motif Chemokine 3-Like 1; Small-Inducible Cytokine A3-Like 1; Tonsillar Lymphocyte LD78 Beta Protein; CCL3L1; D17S1718; G0S19-2; SCYA3L1; CCL3L3	Human	HEK293
	LD78-beta/CCL3L1 Protein, Human (HEK293 His) is a multiallelic copy number variable, which plays a crucial role in immunoregulatory and hosts defense through the production of macrophage inflammatory protein (MIP)-1α.

HY-P73716

	PD-L1 Protein, Mouse (HEK293, His-Fc) Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1	Mouse	HEK293
	PD-L1 protein serves as a ligand for the inhibitory receptor PDCD1/PD-1 and is critical for maintaining immune tolerance. This interaction modulates T cell activation, limits effector responses and may stimulate IL10-producing T cell subsets. PD-L1 Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived PD-L1 protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

HY-P70030

	CHI3L1 Protein, Human (HEK293, His) 4 Publications Verification rHuChitinase-3-like protein 1/CHI3L1, His; Chitinase-3-Like protein 1; 39 kDa Synovial Protein; Cartilage Glycoprotein 39; CGP-39; GP-39; hCGP-39; YKL-40; CHI3L1	Human	HEK293
	The CHI3L1 protein is a binding lectin that lacks chitinase activity. CHI3L1 contributes to tissue remodeling, cellular adaptation to environmental changes, and T helper type 2 inflammatory responses. CHI3L1 also controls hyperoxia-induced injury, inflammation, and epithelial cell apoptosis. CHI3L1 Protein, Human (HEK293, His) is the recombinant human-derived CHI3L1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P705183

	PD-L1 Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1	Cynomolgus	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (75) Rabbit (87)
Reactivity:	Human (156) mouse (2) rat (2) Rat (74) Mouse (92) Monkey (8) Rabbit (2) Dog (2) Pig (1)
Application:	WB FC ICC/IF (1) IHC-P (104) ICC/IF (61) mIHC (2) IF-Tissue (7) IP (27) WB FC (1) IHC-F (13) WB (107) ChIP (1) FC (65) ELISA (36)
Isotype:	IgG (88) IgG1 (48) IgG2a (7) IgG2b (12) IgG,IgG/Kappa (1)
Conjugation:	APC (1) PE (1) Non-conjugated (160) Biotin (11)
Clonality:	YA9804 (1) polyclonal (2) Monoclonal (101) Monoclonal Antibody (3) Recombinant (53)
Modification:	Phosphorylated (3) Unmodified (106)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86680

	PGP9.5 Antibody (YA6372) Gracile axonal dystrophy; Neuron cytoplasmic protein 9.5; Park 5; Park5; Parkinson Disease 5; PGP 9.5; PGP9.5; PGP95; Protein gene product 9.5; Ubiquitin C terminal esterase L1; Ubiquitin C terminal hydrolase(neuron specific); Ubiquitin C terminal hydrolase; Ubiquitin carboxyl terminal esterase L1; Ubiquitin carboxyl terminal hydrolase isozyme L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin thioesterase L1; Ubiquitin thiolesterase; Ubiquitin thiolesterase L1; UCH L1; UCH-L1; UCHL1; UCHL1_HUMAN.	WB, IHC-P, IHC-F, IF-Tissue	Human, Mouse, Rat
	PGP9.5 Antibody (YA6372) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGP9.5.

HY-P85926

	PGP9.5 Antibody (YA5618) Epididymis luminal protein 117; Epididymis secretory protein Li 53; HEL 117; HEL S 53; NDGOA; Neuron cytoplasmic protein 9.5; OTTHUMP00000218137; OTTHUMP00000218139; OTTHUMP00000218140; OTTHUMP00000218141; Park 5; PARK5; PGP 9.5; PGP9.5; PGP95; Protein gene product 9.5; Ubiquitin C terminal esterase L1; Ubiquitin C terminal hydrolase; Ubiquitin C terminal hydrolase L1; Ubiquitin carboxyl terminal esterase L1; Ubiquitin carboxyl terminal hydrolase isozyme L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin thioesterase L1; Ubiquitin thiolesterase; Ubiquitin thiolesterase L1; UCH-L1; UCHL1; UCHL1_HUMAN	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	PGP9.5 Antibody (YA5618) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PGP9.5.

HY-P86838

	Cathepsin L Antibody (YA6531) Cathepsin L antibody; cathepsin L, 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; CTSL1 antibody; Cathepsin L antibody; cathepsin L, 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; CTSL1 antibody; ctsL1b antibody; FLJ31037 antibody; hgg1 antibody; Major excreted protein antibody; MEP antibody; MGC123162 antibody; wu:fb30g09 antibody;	WB, IHC-P, FC	Human, Mouse, Rat, Monkey
	Cathepsin L Antibody (YA6531) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cathepsin L.

HY-P86837

	Cathepsin L/V/K/H Antibody (YA6530) Cathepsin L antibody; cathepsin L 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; Cathepsin L antibody; cathepsin L 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; CTSL1 antibody; ctsL1b antibody; FLJ31037 antibody; hgg1 antibody; Major excreted protein antibody; MEP antibody; MGC123162 antibody; wu:fb30g09 antibody;	IHC-P, IHC-F, IF-Tissue	Human, Mouse
	Cathepsin L/V/K/H Antibody (YA6530) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cathepsin L/V/K/H.

HY-P83404

	L1CAM Antibody (YA3149) L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171	WB, IHC-P	Human
	L1CAM Antibody (YA3149) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to L1CAM.

HY-P85443

	L1CAM Antibody (YA5135) L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171	WB, FC	Human, Mouse, Rat
	L1CAM Antibody (YA5135) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to L1CAM.

HY-P81625

	L1CAM Antibody (YA1370) L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171	FC, ELISA	Human
	L1CAM Antibody (YA1370) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to L1CAM.

HY-P83404A

	L1CAM Antibody (YA3149)(PBS only) L1CAM; CAML1; MIC5; Neural cell adhesion molecule L1; N-CAM-L1; NCAM-L1; CD antigen CD171	WB, IHC-P	Human
	L1CAM Antibody (YA3149) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to L1CAM.

HY-P82148

	APOL1 Antibody (YA1893) APOL1; APOL; Apolipoprotein L1; Apolipoprotein L; Apo-L; ApoL; Apolipoprotein L-I; ApoL-I	WB, ICC/IF, FC, IP	Human
	APOL1 Antibody (YA1893) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to APOL1.

HY-P82149

	S100 alpha9 Antibody (YA1894) S100 alpha9; Calgranulin-B; Leukocyte L1 complex heavy chain	WB, IHC-F, IHC-P, ICC/IF	Mouse
	S100 alpha9 Antibody (YA1894) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100 alpha9.

HY-P82036

	PUM1 Antibody (YA1781) HsPUM; PUM L1; Pum1; PUMH 1; PUMH; PUMH1; Pumilio1; PUML1	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	PUM1 Antibody (YA1781) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PUM1.

HY-P82149A

	S100 alpha9 Antibody (YA1894)(PBS only) S100 alpha9; Calgranulin-B; Leukocyte L1 complex heavy chain	WB, IHC-F, IHC-P, ICC/IF	Mouse
	S100 alpha9 Antibody (YA1894) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100 alpha9.

HY-P82036A

	PUM1 Antibody (YA1781)(PBS only) HsPUM; PUM L1; Pum1; PUMH 1; PUMH; PUMH1; Pumilio1; PUML1	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	PUM1 Antibody (YA1781) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PUM1.

HY-P83734

	S100A9 Antibody(YA3464) Leukocyte L1 complex heavy chain antibody; 60B8AG antibody; CAGB antibody; Calgranulin B antibody; Calgranulin-B antibody; Calprotectin L1H subunit antibody; CFAG antibody; CGLB antibody; Cystic fibrosis antigen B antibody; L1AG antibody; Leukocyte L1 complex heavy chain antibody; LIAG antibody; MAC387 antibody; MIF antibody; Migration inhibitory factor related protein 14 antibody; Migration inhibitory factor-related protein 14 antibody; MRP 14 antibody; MRP-14 antibody; MRP14 antibody; Myeloid-related protein 14 antibody; NIF antibody; OTTHUMP00000015331 antibody; p14 antibody; Protein S100-A9 antibody; S100 A9 antibody; S100 calcium binding protein A9 antibody; S100 calcium binding protein A9 calgranulin B antibody; S100 calcium-binding protein A9 antibody; S100A9 antibody; S10A9_HUMAN antibody;	WB, IHC-P, IF-Tissue, mIHC	Human
	S100A9 Antibody(YA3464) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100A9.

HY-P86684

	PD-L1 Antibody (YA6376) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	WB, IHC-P, IHC-F, IF-Tissue, ICC/IF	Human
	PD-L1 Antibody (YA6376) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751

	PD-L1 Antibody (YA6443) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P89400M

	CD274/PD-L1 Antibody (PE) (YA8851) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P86751A

	PD-L1 Antibody (YA6443)(PBS only) Programmed cell death 1 ligand 1; CD274; B7 H; B7 H1; B7 homolog 1; B7-H1; B7H; B7H1; CD 274; CD274 antigen; CD274 molecule; MGC142294; MGC142296; OTTHUMP00000021029; PD L1; PD1L1_HUMAN; PD1L1_Mouse; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL 1; PDL1; Programmed death ligand 1; RGD1566211.	FC	Human
	PD-L1 Antibody (YA6443) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P81425

	S100 A8 Antibody (YA1170) Calgranulin-A antibody; Calprotectin L1L subunit antibody; CFAG antibody; Cystic fibrosis antigen antibody; Leukocyte L1 complex light chain antibody; Migration inhibitory factor-related protein 8 antibody; MRP-8 antibody; N-terminally processed antibody; p8 antibody; Protein S100-A8 antibody; S100 calcium-binding protein A8 antibody; S100A8 antibody; S10A8_HUMAN antibody; Urinary stone protein band A antibody	WB, IHC-P, ICC/IF, IP, FC, IF-Tissue	Human
	S100 A8 Antibody (YA1170) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100 A8.

HY-P87006

	PD-L1 Antibody (YA6699) B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody;	WB, IHC-P, mIHC	Mouse
	PD-L1 Antibody (YA6699) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P87076

	SMC2 Antibody (YA6769) CAP E antibody; CAPE antibody; Chromosome associated protein E antibody; Chromosome-associated protein E antibody; FLJ10093 antibody; hCAP E antibody; hCAP-E antibody; hCAPE antibody; PRO0324 antibody; SMC 2 antibody; CAP E antibody; CAPE antibody; Chromosome associated protein E antibody; Chromosome-associated protein E antibody; FLJ10093 antibody; hCAP E antibody; hCAP-E antibody; hCAPE antibody; PRO0324 antibody; SMC 2 antibody; SMC protein 2 antibody; SMC-2 antibody; SMC2 antibody; SMC2 L1 antibody; SMC2_HUMAN antibody; SMC2L1 antibody; Structural maintenance of chromosomes (SMC) family member chromosome associated protein E antibody; Structural maintenance of chromosomes 2 antibody; Structural maintenance of chromosomes 2 like 1 antibody; Structural maintenance of chromosomes 2 yeast like 1 antibody; Structural maintenance of chromosomes protein 2 antibody; XCAP E homolog antibody; XCAP-E homolog antibody; XCAPE homolog antibody;	WB, IHC-P, ICC/IF	Human, Monkey
	SMC2 Antibody (YA6769) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SMC2.

HY-P81513

	CD163L1 Antibody (YA1258) CD163b; CD163L1; CD164L1; M160; Scart1;	IHC-P	Human
	CD163L1 Antibody (YA1258) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD163L1.

HY-P810534-APC

	CD274/PD-L1 Antibody (APC) (YA9804） CD274/PD-L1	FC	Human

HY-P81513A

	CD163L1 Antibody (YA1258)(PBS only) CD163b; CD163L1; CD164L1; M160; Scart1;	IHC-P	Human
	CD163L1 Antibody (YA1258) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD163L1.

HY-P84842

	PD-L1 Antibody (YA4539) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P88840

	RAD51L1 Antibody (YA8524) R51H2; RAD51L1; REC2	ICC/IF, FC	Human, Mouse
	RAD51L1 Antibody (YA8524) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RAD51L1.

HY-P80273

	PD-L1 Antibody (YA235)	WB, IHC-P	Human
	PD-L1 Antibody (YA235) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

HY-P83318

	MAD2L1 Binding Protein Antibody (YA3063) MAD2L1BP; CMT2; KIAA0110; MAD2L1-binding protein; Caught by MAD2 protein	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	MAD2L1 Binding Protein Antibody (YA3063) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAD2L1 Binding Protein.

HY-P84842A

	PD-L1 Antibody (YA4539)(PBS only) B7-H; B7H1; PDL1; PD-L1; PDCD1L1; PDCD1LG1,CD274	IHC-P, FC, ELISA	Human
	PD-L1 Antibody (YA4539) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PD-L1.

HY-P83294

	LINE-1 ORF1p Antibody (YA3039) L1ORF1p; L1RE1; LRE1	WB, ICC/IF, IP	Human
	LINE-1 ORF1p Antibody (YA3039) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LINE-1 ORF1p.

HY-P88409

	AK3 Antibody (YA8093) AK3L1; AK6; AKL3L; AKL3L1; FIX	IHC-P, ICC/IF, FC	Human, Mouse, Rat
	AK3 Antibody (YA8093) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AK3.

HY-P88840A

	RAD51L1 Antibody (YA8524)(PBS only) R51H2; RAD51L1; REC2	ICC/IF, FC	Human, Mouse
	RAD51L1 Antibody (YA8524) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RAD51L1.

HY-P87600

	Mad2L1 Antibody (YA7284)	ICC/IF	Human
	Mad2L1 Antibody (YA7284) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Mad2L1.

HY-P87978

	CD163L1 Antibody (YA7663)	IHC-P, IHC-F, IF-Tissue
	CD163L1 Antibody (YA7663) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD163L1.

HY-P88041

	NAP1L1 Antibody (YA7726)	WB, IHC-P, IHC-F, IF-Tissue, FC, ICC/IF	Human, Mouse, Rat
	NAP1L1 Antibody (YA7726) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NAP1L1.

HY-P82948

	AK3L1 Antibody (YA2693) AK3; AK 4; AK3L1; AK3L2	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	AK3L1 Antibody (YA2693) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AK3L1.

HY-P83294A

	LINE-1 ORF1p Antibody (YA3039)(PBS only) L1ORF1p; L1RE1; LRE1	WB, IP	Human
	LINE-1 ORF1p Antibody (YA3039) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LINE-1 ORF1p.

HY-P88409A

	AK3 Antibody (YA8093)(PBS only) AK3L1; AK6; AKL3L; AKL3L1; FIX	IHC-P, ICC/IF, FC	Human, Mouse, Rat
	AK3 Antibody (YA8093) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AK3.

HY-P82948A

	AK3L1 Antibody (YA2693)(PBS only) AK3; AK 4; AK3L1; AK3L2	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	AK3L1 Antibody (YA2693) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AK3L1.

HY-P88182

	PRMT2 Antibody (YA7866) HRMT1L1	IHC-P, ICC/IF	Human, Mouse, Rat
	PRMT2 Antibody (YA7866) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PRMT2.

HY-P82704

	MAD1L1 Antibody (YA2449) hMAD1; HsMAD1; MAD1; MAD1L1; PIG9; TP53I9; TXBP181	WB	Human, Mouse, Rat
	MAD1L1 Antibody (YA2449) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAD1L1.

HY-P88353

	ZBTB4 Antibody (YA8037) KAISO-L1; ZNF903	IHC-P	Human, Mouse, Rat
	ZBTB4 Antibody (YA8037) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ZBTB4.

HY-P82442

	Atg16L1 Antibody (YA2187) ATG16L1; APG16L; Autophagy-related protein 16-1; APG16-like 1	WB	Human, Mouse, Rat
	Atg16L1 Antibody (YA2187) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Atg16L1.

HY-P86193

	Atg16L1 Antibody (YA5885) ATG16L1; APG16L; Autophagy-related protein 16-1; APG16-like 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Atg16L1 Antibody (YA5885) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Atg16L1.

HY-P84728

	SIRT1 Antibody (YA4425) 1 Publications Verification SIR2L1; SIRT1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Rat, Rabbit, Monkey
	SIRT1 Antibody (YA4425) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SIRT1.

HY-P84811

	CD248 Antibody (YA4508) TEM1; CD164L1	FC, ELISA	Human
	CD248 Antibody (YA4508) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD248.

HY-P88986

	ATXN7L1 Antibody (YA8670) ATXN7L4	IHC-P	Human, Mouse, Rat
	ATXN7L1 Antibody (YA8670) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ATXN7L1.

HY-P89153

	PGM2L1 Antibody (YA8837) BM32A; PMMLP	IHC-P	Human, Mouse, Rat
	PGM2L1 Antibody (YA8837) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PGM2L1.

HY-P88182A

	PRMT2 Antibody (YA7866)(PBS only) HRMT1L1	IHC-P, ICC/IF	Human, Mouse, Rat
	PRMT2 Antibody (YA7866) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PRMT2.

HY-P81614

	Bcl-XL Antibody (YA1359) BCL2L1; BCL2L; BCLX; Bcl-2-like protein 1; Bcl2-L-1; Apoptosis regulator Bcl-X	FC, ELISA	Human
	Bcl-XL Antibody (YA1359) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-XL.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145746

Sulfo-Cy5 azide		Labeling and Fluorescence Imaging Azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of *PD-L1* in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) ^[1] .

HY-P10950

PD-L1 inhibitory peptide		Alkynes
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers ^[1] .

HY-169392

D5B		DBCO
D5B is a potent and selective *PD-L1* inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity ^[1].

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

Cat. No.	Product Name		Classification

HY-132580

Tofersen 2 Publications Verification BIIB067; ISIS-SOD1Rx; ISIS 333611		Antisense Oligonucleotides
Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC₅₀ of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis ^[1] .

HY-132580A

Tofersen sodium 2 Publications Verification BIIB067 sodium; ISIS-SOD1Rx sodium; ISIS 333611 sodium		Antisense Oligonucleotides
Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC₅₀ of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis ^[1] .

HY-177653A

Opemalirsen sodium AZD2373 sodium, ION-972190 sodium		Antisense Oligonucleotides
Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

HY-177653

Opemalirsen AZD2373, ION-972190		Antisense Oligonucleotides
Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

HY-177801

XQ-P3 sodium		Aptamers
XQ-P3 sodium is an aptamer that binds to PD-L1. XQ-P3 can inhibit the PD-1/PD-L1 interaction and restore the function of T cells to detect and attack tumor cells.

HY-177620

Cadapersen RG6084; RO-7191863		Antisense Oligonucleotides
Cadapersen (RG6084) is an antisense oligonucleotide that induces the degradation of PD-L1 mRNA. It is used for the study of chronic hepatitis B (CHB).

HY-132580S

Tofersen-d27 BIIB067-d₂₇; ISIS-SOD1Rx-d₂₇; ISIS 333611-d₂₇		Antisense Oligonucleotides
Tofersen-d₂₇ (BIIB067-d₂₇) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC₅₀ of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.

HY-RS18070

L1cam Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
L1cam Mouse Pre-designed siRNA Set A contains three designed siRNAs for L1cam gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03492

CYRIB Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CYRIB Human Pre-designed siRNA Set A contains three designed siRNAs for CYRIB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174752

Human CCL4L1 mRNA		mRNA Chemokine & Receptors
Human CCL4L1 mRNA encodes the human C-C motif chemokine ligand 4 like 1 (CCL4L1) protein, a chemokine that can induce chemotaxis of cells expressing CCR5 or CCR1.

HY-174753

Human CCL3L1 mRNA		mRNA Chemokine & Receptors
Human CCL3L1 mRNA encodes the human C-C motif chemokine ligand 3 like 1 (CCL3L1) protein. It is a ligand for CCR1, CCR3 and CCR5.

HY-RS07481

L1CAM Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
L1CAM Human Pre-designed siRNA Set A contains three designed siRNAs for L1CAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS24545

L1cam Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
L1cam Rat Pre-designed siRNA Set A contains three designed siRNAs for L1cam gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15929

YME1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
YME1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for YME1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS07482

L1TD1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
L1TD1 Human Pre-designed siRNA Set A contains three designed siRNAs for L1TD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS27788

Zfp36l1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Zfp36l1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Zfp36l1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS04950

FIP1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
FIP1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for FIP1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS21892

Nap1l1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Nap1l1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nap1l1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03150

CREB3L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CREB3L1 Human Pre-designed siRNA Set A contains three designed siRNAs for CREB3L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01421

BCL2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
BCL2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS09244

NFE2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NFE2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for NFE2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02298

CDC37L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CDC37L1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDC37L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01354

BAIAP2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
BAIAP2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for BAIAP2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS26329

Atg16l1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Atg16l1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Atg16l1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS05710

GPR37L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
GPR37L1 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR37L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS07948

MAD1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAD1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAD1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS07949

MAD2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAD2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAD2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS15318

UAP1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
UAP1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for UAP1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS27075

Mad2l1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Mad2l1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mad2l1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS14309

TCF7L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TCF7L1 Human Pre-designed siRNA Set A contains three designed siRNAs for TCF7L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10169

PCP4L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PCP4L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PCP4L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08593

MORF4L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MORF4L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MORF4L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12606

SEC14L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SEC14L1 Human Pre-designed siRNA Set A contains three designed siRNAs for SEC14L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS14416

TFCP2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TFCP2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for TFCP2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS07938

MAB21L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAB21L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MAB21L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS17515

Npc1l1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Npc1l1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Npc1l1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01143

ATG16L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ATG16L1 Human Pre-designed siRNA Set A contains three designed siRNAs for ATG16L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS20566

Mad2l1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Mad2l1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mad2l1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS01422

Bcl2l1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Bcl2l1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bcl2l1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10422

PHF20L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PHF20L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PHF20L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12174

RPL22L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
RPL22L1 Human Pre-designed siRNA Set A contains three designed siRNAs for RPL22L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS04455

EPS8L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
EPS8L1 Human Pre-designed siRNA Set A contains three designed siRNAs for EPS8L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS14041

SUPV3L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SUPV3L1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUPV3L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS09667

NUDT16L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NUDT16L1 Human Pre-designed siRNA Set A contains three designed siRNAs for NUDT16L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12588

SDF2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SDF2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for SDF2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10594

PKD2L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PKD2L1 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12929

SIPA1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SIPA1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for SIPA1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS02103

CCL4L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CCL4L1 Human Pre-designed siRNA Set A contains three designed siRNAs for CCL4L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08604

MOV10L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MOV10L1 Human Pre-designed siRNA Set A contains three designed siRNAs for MOV10L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12139

RP1L1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
RP1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for RP1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

L1

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products